Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- momelotinib
- Viberzi (eluxadoline)
Interactions between your drugs
eluxadoline momelotinib
Applies to: Viberzi (eluxadoline), momelotinib
Eluxadoline may increase the blood levels and effects of momelotinib. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as fever, chills, cough, chest pain, shortness of breath (with or without chest discomfort), diarrhea, dizziness, fatigue, pain, redness or swelling in an extremity, nausea or vomiting, unusual bruising or bleeding, dark urine, or pain on the right side of the abdomen. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
eluxadoline food
Applies to: Viberzi (eluxadoline)
Eluxadoline should be taken twice daily with food. You should avoid excessive alcohol use during treatment with eluxadoline. Consumption of more than 3 alcoholic beverages per day while taking eluxadoline may increase the risk of pancreatitis, or inflammation of the pancreas. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders. Symptoms of pancreatitis usually go away when treatment with eluxadoline is stopped.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Ojjaara
Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Inrebic
Inrebic is used to treat certain types of myelofibrosis (MF) in adults. It is an oral capsule taken ...
Fedratinib
Fedratinib is used for certain types of myelofibrosis (MF) in adults, relieving night sweats ...
Pacritinib
Pacritinib (brand name Vonjo) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.